April 18, 2022

Ensysce Biosciences Announces Appointment of Dr. Nily Osman as Chief Medical Officer

SAN DIEGO, CA / ACCESSWIRE / April 18, 2022/ Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety and performance with a current focus on reducing abuse and overdose, today announced the appointment of Dr. Nily Osman as Chief Medical Officer effective April 18, 2022. Dr. Osman will succeed Dr. William Schmidt as he transitions to Senior VP of Clinical Development and continues his role on the Company's clinical advisory board.

Dr. Osman, a highly versatile board-certified neurologist, migraine and pain specialist, has over ten years of experience in both R&D and medical affairs within the pharmaceutical, CRO and medical device industries. Dr. Osman was previously the Senior Medical Director at Scholar Rock where she led their program for spinal muscular atrophy and was a practicing neurologist and academic researcher at the University of Toronto. She recently returned from Poland where she spent several weeks leveraging her medical expertise providing care to Ukrainian refugees. Dr. Osman completed her residency at University of Ottawa in adult neurology and a fellowship in headache pain medicine at the University of Toronto. She received her M.D. degree from Jagellonian Medical College in Poland, and her B.S. from the University of Guelph, Canada.

Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce, commented, "It is my pleasure to welcome Nily to the Ensysce team as we progress and expand our clinical trials in the development of our abuse and overdose-protected pain products. She brings significant expertise and a proven track record in pain and pain management. Her experience in neurology, as well as within the pharmaceutical industry, makes her an extremely valuable addition to Ensysce at such an important time in the Company's history."

Dr. Lynn Kirkpatrick concluded, "I am also extremely grateful for Dr. Schmidt's contributions to our clinical programs. He has been instrumental in our path towards commercialization, and I look forward to our continued working relationship in his role as Senior VP of Clinical Development."

Dr. Osman added, "I am delighted to have the opportunity to work with Lynn and join the very talented team at Ensysce and be part of the Company's mission to launch the next generation opioid products. As the Company progresses on its clinical trials, I look forward to leveraging my direct industry experience as I believe this is truly an exciting time to join the Company with several key milestones approaching."

About Ensysce Biosciences

Ensysce Biosciences, based in San Diego, CA is a clinical-stage biotech company using its two novel proprietary technology platforms to develop safer prescription drugs. Leveraging its Trypsin-Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR™) platforms, the Company is developing next-generation, tamper-proof opioids that prevent both drug abuse and overdoses. Ensysce's products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing the human and economic costs. The platforms are covered by an extensive worldwide intellectual property portfolio encompassing a wide array of prescription drugs. For more information, please visit www.ensysce.com.

Forward-Looking Statements

Statements contained in this press release that are not purely historical may be deemed to be forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Without limiting the foregoing, the use of words such as "may," "intends," "can," "might," "will," "expect," "plan," and other similar expressions are intended to identify forward-looking statements. The product candidates discussed are in clinic and not approved and there can be no assurance that the clinical programs will be successful in demonstrating safety and/or efficacy, that Ensysce will not encounter problems or delays in clinical development, or that any product candidate will ever receive regulatory approval or be successfully commercialized. All forward-looking statements are based on estimates and assumptions by Ensysce's management that, although Ensysce believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Ensysce expected. In addition, Ensysce's business is subject to additional risks and uncertainties, including among others, the initiation and conduct of preclinical studies and clinical trials; the timing and availability of data from preclinical studies and clinical trials; expectations for regulatory submissions and approvals; potential safety concerns related to, or efficacy of, Ensysce's product candidates; the availability or commercial potential of product candidates; the ability of Ensysce to fund its continued operations, including its planned clinical trials; the dilutive effect of stock issuances from our fundraising; and Ensysce's and its partners' ability to perform under their license, collaboration and manufacturing arrangements. These statements are also subject to a number of material risks and uncertainties that are described in Ensysce's most recent annual report on Form 10-K and current reports on Form 8-K, which are available, free of charge, at the SEC's website at www.sec.gov. Any forward-looking statement speaks only as of the date on which it was made. Ensysce undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required under applicable law.

Ensysce Biosciences Company Contact:
Lynn Kirkpatrick, Ph.D.
Chief Executive Officer
(858) 263-4196

Ensysce Biosciences Investor Relations Contact:
Shannon Devine
MZ North America
Main: 203-741-8811

ENSC@mzgroup.us

SOURCE: Ensysce Biosciences Inc.

View source version on accesswire.com:
https://www.accesswire.com/697814/Ensysce-Biosciences-Announces-Appointment-of-Dr-Nily-Osman-as-Chief-Medical-Officer